NASDAQ:SRNE - Sorrento Therapeutics Stock Price, Price Target & More

Get Started

$7.85 -0.10 (-1.26 %)

(As of 05/28/2018 06:02 AM ET)

Previous Close$7.95

Today's Range$7.70 - $8.20

52-Week Range$1.50 - $10.65

Volume1.73 million shs

Average Volume1.74 million shs

Market Capitalization$728.68 million

P/E RatioN/A

Dividend YieldN/A

Beta2.4

About Sorrento Therapeutics (NASDAQ:SRNE)

Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. The company is focusing on the development of chimeric antigen receptor (CAR)-based immunotherapies using autologous T-cells. It is developing CD38 Directed CAR-T, a cellular therapy used for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases; CD123 Directed CAR-T for the treatment of acute myelogenous leukemia; and human antibodies, including PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2, OX40, TIGIT, and CD137. The company is also developing intracellular targeting antibodies comprising STAT3, Mutant KRAS, MYC, p53, and TAU to modulate the evolution of cancer, inflammation, autoimmune diseases, diabetes, central nervous system diseases, cardiovascular diseases, and viral infections; and oncolytic viruses that infect and selectively multiply in and destroy tumor cells without damaging healthy tissue. In addition, it offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. The company has a licensing agreement with Mabtech Limited to develop and commercialize multiple prespecified biosimilar and biobetter antibodies from based on Erbitux, Remicade, Xolair, and Simulect. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.

Receive SRNE News and Ratings via Email

Sign-up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:SRNE

CUSIPN/A

Webwww.sorrentotherapeutics.com

Phone858-203-4100

Debt

Debt-to-Equity Ratio0.02

Current Ratio0.71

Quick Ratio0.71

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$151.85 million

Price / Sales4.80

Cash Flow$0.2255 per share

Price / Cash34.81

Book Value$2.59 per share

Price / Book3.03

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$9.13 million

Net Margins23.25%

Return on Equity21.31%

Return on Assets8.09%

Miscellaneous

Employees162

Outstanding Shares92,820,000

Sorrento Therapeutics (NASDAQ:SRNE) Frequently Asked Questions

What is Sorrento Therapeutics' stock symbol?

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

How were Sorrento Therapeutics' earnings last quarter?

Sorrento Therapeutics (NASDAQ:SRNE) issued its earnings results on Monday, November, 16th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter. The biopharmaceutical company had revenue of $1.10 million for the quarter, compared to the consensus estimate of $1.28 million. Sorrento Therapeutics had a return on equity of 21.31% and a net margin of 23.25%. View Sorrento Therapeutics' Earnings History.

What price target have analysts set for SRNE?

5 equities research analysts have issued 12-month price objectives for Sorrento Therapeutics' shares. Their predictions range from $7.00 to $40.00. On average, they anticipate Sorrento Therapeutics' stock price to reach $15.75 in the next year. View Analyst Ratings for Sorrento Therapeutics.

Are investors shorting Sorrento Therapeutics?

Sorrento Therapeutics saw a increase in short interest during the month of April. As of April 30th, there was short interest totalling 16,542,568 shares, an increase of 9.5% from the April 13th total of 15,102,074 shares. Based on an average trading volume of 2,141,013 shares, the short-interest ratio is currently 7.7 days. Currently, 25.3% of the company's shares are short sold.

Who are some of Sorrento Therapeutics' key competitors?

Some companies that are related to Sorrento Therapeutics include Intrexon (XON), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Pieris Pharmaceuticals (PIRS), Eloxx Pharmaceuticals (ELOX), Viralytics (VRACY), Anavex Life Sciences (AVXL), HedgePath Pharmaceuticals (HPPI), Luna Innovations (LUNA), Senomyx (SNMX), Dyadic International, Inc common stock (DYAI), Cleveland BioLabs (CBLI), BIOQUAL (BIOQ) and Vitality Biopharma (VBIO).

Who are Sorrento Therapeutics' key executives?

Sorrento Therapeutics' management team includes the folowing people:

Dr. Henry H. Ji, Co-Founder, Chairman, CEO & Pres (Age 54)
Mr. George K. Ng, Exec. VP, Chief Admin. Officer & Chief Legal Officer (Age 44)
Dr. Jerome Bernard Zeldis, Chief Medical Officer and Pres of Clinical Research, Medical Affairs & Regulatory (Age 68)
Mr. Jiong Shao CFA, Exec. VP & CFO (Age 50)
Dr. Alexis Nahama, VP of Corp. Devel.

Has Sorrento Therapeutics been receiving favorable news coverage?

Media coverage about SRNE stock has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sorrento Therapeutics earned a news sentiment score of 0.18 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 46.85 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are Sorrento Therapeutics' major shareholders?

Sorrento Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (2.40%), Millennium Management LLC (1.55%), Wells Fargo & Company MN (0.55%), UBS Group AG (0.48%), Alambic Investment Management L.P. (0.46%) and Candriam Luxembourg S.C.A. (0.34%). Company insiders that own Sorrento Therapeutics stock include Abg Management Ltd, George K Ng, Henry Ji, Jaisim Shah, Jerome B Zeldis, Kevin Herde, Pacific Medtech (Bvi) Ltd Asia, Patrick Soon-Shiong and Yue Alexander Wu. View Institutional Ownership Trends for Sorrento Therapeutics.

Which institutional investors are buying Sorrento Therapeutics stock?

SRNE stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Wells Fargo & Company MN, UBS Group AG, Alambic Investment Management L.P., Candriam Luxembourg S.C.A., A.R.T. Advisors LLC, GSA Capital Partners LLP and Citigroup Inc.. Company insiders that have bought Sorrento Therapeutics stock in the last two years include Abg Management Ltd, George K Ng, Henry Ji, Jaisim Shah, Jerome B Zeldis, Kevin Herde and Yue Alexander Wu. View Insider Buying and Selling for Sorrento Therapeutics.

How do I buy shares of Sorrento Therapeutics?

Shares of SRNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sorrento Therapeutics' stock price today?

One share of SRNE stock can currently be purchased for approximately $7.85.

How big of a company is Sorrento Therapeutics?

Sorrento Therapeutics has a market capitalization of $728.68 million and generates $151.85 million in revenue each year. Sorrento Therapeutics employs 162 workers across the globe.

How can I contact Sorrento Therapeutics?

Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-203-4100 or via email at [email protected]

MarketBeat Community Rating for Sorrento Therapeutics (SRNE)

Community Ranking:		3.6 out of 5 ( )
Outperform Votes:		322 (Vote Outperform)
Underperform Votes:		124 (Vote Underperform)
Total Votes:		446

MarketBeat's community ratings are surveys of what our community members think about Sorrento Therapeutics and other stocks. Vote "Outperform" if you believe SRNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRNE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Sorrento Therapeutics (NASDAQ:SRNE) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

5 Wall Street analysts have issued ratings and price targets for Sorrento Therapeutics in the last 12 months. Their average twelve-month price target is $15.75, suggesting that the stock has a possible upside of 100.64%. The high price target for SRNE is $40.00 and the low price target for SRNE is $7.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$15.75	$15.3333	$13.6667	$11.50
Price Target Upside:	100.64% upside	153.44% upside	91.95% upside	400.00% upside

Sorrento Therapeutics (NASDAQ:SRNE) Consensus Price Target History

Price Target History for Sorrento Therapeutics (NASDAQ:SRNE)

Sorrento Therapeutics (NASDAQ:SRNE) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/14/2018	HC Wainwright	Set Price Target	Buy	$40.00	Low
1/19/2018	Oppenheimer	Reiterated Rating	Buy	$9.00	High
8/3/2017	Roth Capital	Initiated Coverage	Buy	$7.00	High
8/3/2017	UBS	Initiated Coverage	Outperform	$7.00	High
6/17/2017	FBR & Co	Reiterated Rating	Buy		Low
5/22/2017	Rodman & Renshaw	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $20.00	High
8/12/2016	Brean Capital	Reiterated Rating	Buy		N/A

(Data available from 5/28/2016 forward)

Sorrento Therapeutics (NASDAQ:SRNE) Earnings History and Estimates Chart

Earnings by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)

Sorrento Therapeutics (NASDAQ:SRNE) Earnings Estimates

2018 EPS Consensus Estimate: ($0.58)
2019 EPS Consensus Estimate: ($0.41)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.17)	($0.17)	($0.17)
Q2 2018	1	($0.16)	($0.16)	($0.16)
Q3 2018	1	($0.15)	($0.15)	($0.15)
Q4 2018	1	($0.10)	($0.10)	($0.10)
Q1 2019	1	($0.12)	($0.12)	($0.12)
Q2 2019	1	($0.10)	($0.10)	($0.10)
Q3 2019	1	($0.10)	($0.10)	($0.10)
Q4 2019	1	($0.09)	($0.09)	($0.09)

Sorrento Therapeutics (NASDAQ SRNE) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/9/2017	Q3 2017		$0.44		$121.91 million	View	N/A
8/9/2017	Q2 2017		($0.20)		$4.67 million	View	N/A
5/15/2017	Q1 2017	($0.33)	($0.45)	$4.02 million	$4.87 million	View	N/A
3/21/2017	Q4 2016	($0.27)	($0.44)	$2.99 million	$4.02 million	View	N/A
11/9/2016	Q3 2016		($0.19)		$2.24 million	View	N/A
8/8/2016	Q2 2016	($0.17)	($0.28)	$1.11 million	$0.90 million	View	N/A
5/10/2016	Q1 2016	($0.37)	($0.63)	$1.34 million	$0.99 million	View	N/A
3/15/2016	Q4 2015		($0.63)		$1.34 million	View	N/A
11/16/2015	Q315		($0.03)	$1.28 million	$1.10 million	View	N/A
8/7/2015	Q2 2015	($0.32)	($0.30)	$0.95 million	$1.17 million	View	N/A
5/5/2015	Q1 2015	($0.14)	($0.29)	$5.85 million	$0.98 million	View	N/A
3/13/2015	Q4 2014		($0.28)		$0.80 million	View	N/A
11/4/2014	Q314	($0.32)	($0.27)	$0.08 million	$1.28 million	View	N/A
8/6/2014		($0.34)	($0.33)	$0.08 million	$0.78 million	View	N/A
5/14/2014		($0.29)	($0.44)	$0.12 million	$0.98 million	View	N/A
4/1/2014	Q4 2013	($0.28)	($0.35)		$0.10 million	View	N/A
11/14/2013	Q3 2013	($0.28)	($0.23)		$0.08 million	View	N/A
8/13/2013	Q2 2013		($0.26)		$0.14 million	View	N/A
5/15/2013	Q1 2013		($0.01)		$0.13 million	View	N/A

(Earnings results data provided by Zacks Investment Research)

Sorrento Therapeutics (NASDAQ:SRNE) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Sorrento Therapeutics (NASDAQ SRNE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.00%
Institutional Ownership Percentage: 25.01%

Insider Trading History for Sorrento Therapeutics (NASDAQ:SRNE)

Institutional Ownership by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)

Sorrento Therapeutics (NASDAQ SRNE) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/28/2018	George K Ng	Insider	Buy	90,000	$9.95	$895,500.00	1,906,177
2/7/2018	Abg Management Ltd	Major Shareholder	Sell	150,000	$7.19	$1,078,500.00
2/5/2018	Abg Management Ltd	Major Shareholder	Sell	70,721	$8.00	$565,768.00
1/30/2018	Abg Management Ltd	Major Shareholder	Sell	310,000	$7.64	$2,368,400.00
1/24/2018	Pacific Medtech (Bvi) Ltd Asia	Major Shareholder	Sell	684,288	$7.56	$5,173,217.28
6/15/2017	Henry Ji	Insider	Buy	29,001	$1.81	$52,491.81	139,776
6/15/2017	Jaisim Shah	Director	Buy	10,002	$1.79	$17,903.58	112,633
4/19/2017	Abg Management Ltd	Major Shareholder	Buy	550,000	$2.00	$1,100,000.00
4/19/2017	Henry Ji	CEO	Buy	100,000	$2.00	$200,000.00	139,776
4/13/2017	Abg Management Ltd	Major Shareholder	Buy	2,500,000	$2.00	$5,000,000.00
2/22/2017	Henry Ji	Insider	Buy	2,000	$5.60	$11,200.00	39,776
2/10/2017	Henry Ji	Insider	Buy	20,000	$5.15	$103,000.00	37,776
2/3/2017	Jerome B Zeldis	Insider	Buy	10,000	$5.15	$51,500.00	10,000
2/3/2017	Kevin Herde	VP	Buy	3,000	$5.15	$15,450.00	7,000
2/3/2017	Yue Alexander Wu	Director	Buy	5,000	$5.15	$25,750.00	5,000
6/29/2016	Patrick Soon-Shiong	Major Shareholder	Sell	3,400	$5.82	$19,788.00	720,174
6/23/2016	Patrick Soon-Shiong	Major Shareholder	Sell	6,901	$5.85	$40,370.85	720,174
6/15/2016	Patrick Soon-Shiong	Major Shareholder	Sell	19,836	$5.87	$116,437.32	720,174
6/14/2016	Patrick Soon-Shiong	Major Shareholder	Sell	53,764	$6.14	$330,110.96	736,146
6/13/2016	Patrick Soon-Shiong	Major Shareholder	Sell	37,792	$6.15	$232,420.80	736,146
3/7/2016	Patrick Soon-Shiong	Major Shareholder	Sell	100,000	$6.19	$619,000.00	859,238
8/26/2015	Henry Ji	CEO	Buy	500	$0.95	$475.00	500
8/24/2015	Henry Ji	CEO	Buy	8,888	$12.84	$114,121.92	17,776
8/21/2015	Henry Ji	CEO	Buy	8,888	$13.08	$116,255.04	14,888
11/10/2014	Henry Ji	CEO	Buy	5,999	$4.83	$28,975.17
11/7/2014	Henry Ji	CEO	Buy	4,000	$4.56	$18,240.00
11/6/2014	Henry Ji	CEO	Buy	3,000	$4.53	$13,590.00
12/5/2013	Henry Ji	CEO	Buy	1,000	$8.92	$8,920.00
12/4/2013	Henry Ji	CEO	Buy	1,000	$8.54	$8,540.00
11/25/2013	Jaisim Shah	Director	Buy	1,000	$8.65	$8,650.00
11/22/2013	Henry Ji	CEO	Buy	1,000	$8.47	$8,470.00
11/22/2013	Opko Health, Inc.	Major Shareholder	Sell	8,471	$8.50	$72,003.50
11/21/2013	George Uy	Insider	Buy	3,000	$8.36	$25,080.00
11/21/2013	Opko Health, Inc.	Major Shareholder	Sell	4,269	$8.53	$36,414.57
11/20/2013	Opko Health, Inc.	Major Shareholder	Sell	17,062	$8.75	$149,292.50
11/19/2013	George Uy	Insider	Buy	2,031	$8.61	$17,486.91
11/19/2013	Henry Ji	CEO	Buy	2,000	$8.59	$17,180.00
11/19/2013	Jaisim Shah	Director	Buy	1,000	$9.00	$9,000.00
11/15/2013	Opko Health, Inc.	Major Shareholder	Sell	2,710	$8.75	$23,712.50
11/14/2013	Opko Health, Inc.	Major Shareholder	Sell	1,900	$8.75	$16,625.00
11/13/2013	Opko Health, Inc.	Major Shareholder	Sell	13,457	$8.75	$117,748.75
11/8/2013	Opko Health, Inc.	Major Shareholder	Sell	2,000	$8.75	$17,500.00
11/7/2013	Opko Health, Inc.	Major Shareholder	Sell	120,380	$9.03	$1,087,031.40

(Data available from 1/1/2013 forward)

Sorrento Therapeutics (NASDAQ SRNE) News Headlines

Source:

Date	Headline
	Brokerages Anticipate Sorrento Therapeutics (SRNE) Will Post Quarterly Sales of $5.05 Million www.americanbankingnews.com - May 26 at 3:32 AM
	Analysts Anticipate Sorrento Therapeutics (SRNE) to Post -$0.17 Earnings Per Share www.americanbankingnews.com - May 24 at 10:18 AM
	Reviewing Sorrento Therapeutics (SRNE) & Viralytics (VRACY) www.americanbankingnews.com - May 24 at 1:22 AM
	Critical Contrast: Syneos Health (SYNH) and Sorrento Therapeutics (SRNE) www.americanbankingnews.com - May 22 at 7:04 PM
	HC Wainwright Reiterates "Buy" Rating for Sorrento Therapeutics (SRNE) www.americanbankingnews.com - May 14 at 11:41 AM
	Sorrento Therapeutics (SRNE) Short Interest Up 9.5% in April www.americanbankingnews.com - May 12 at 1:06 AM
	Sorrento Therapeutics (SRNE) Expected to Announce Quarterly Sales of $5.05 Million www.americanbankingnews.com - May 9 at 5:09 AM
	Sorrento Therapeutics (SRNE) Given Average Recommendation of "Buy" by Brokerages www.americanbankingnews.com - May 5 at 1:48 AM
	Sorrento Therapeutics (SRNE) Given a $40.00 Price Target at HC Wainwright www.americanbankingnews.com - May 4 at 10:31 PM
	Cutting Our Losses www.forbes.com - April 30 at 5:13 PM
	Sorrento Therapeutics (SRNE) Upgraded to Buy by BidaskClub www.americanbankingnews.com - April 27 at 11:56 AM
	Malvern biopharm firm developing 'patch-in-a-can' pain relief product www.bizjournals.com - April 27 at 8:30 AM
	Sorrento Therapeutics (SRNE) China CAR-T Spin, Listing Could Dwarf US Market Cap - Evercore ISI www.streetinsider.com - April 27 at 8:30 AM
	Sorrento Therapeutics (SRNE) Short Interest Update www.americanbankingnews.com - April 26 at 2:22 AM
	Sorrento Therapeutics CEO Dr. Henry Ji Invited to the Fourth International Vatican Conference on “Unite to Cure” finance.yahoo.com - April 23 at 8:16 AM
	Financial Comparison: Intrexon (XON) versus Sorrento Therapeutics (SRNE) www.americanbankingnews.com - April 21 at 1:36 PM
	$5.05 Million in Sales Expected for Sorrento Therapeutics (SRNE) This Quarter www.americanbankingnews.com - April 21 at 1:56 AM
	Sorrento Therapeutics (SRNE) Given a $20.00 Price Target at HC Wainwright www.americanbankingnews.com - April 20 at 2:25 PM
	Zacks: Brokerages Expect Sorrento Therapeutics (SRNE) Will Post Earnings of -$0.17 Per Share www.americanbankingnews.com - April 19 at 11:12 PM
	Cramer's lightning round: Take a long-term view on Spotif... finance.yahoo.com - April 17 at 8:32 AM
	Sorrento Therapeutics (SRNE) Upgraded by TheStreet to C- www.americanbankingnews.com - April 17 at 8:17 AM
	Financial Contrast: Luna Innovations (LUNA) & Sorrento Therapeutics (SRNE) www.americanbankingnews.com - April 13 at 1:30 PM
	Sorrento Therapeutics (SRNE) Given a $40.00 Price Target by HC Wainwright Analysts www.americanbankingnews.com - April 12 at 11:17 AM
	Short Interest in Sorrento Therapeutics Inc (SRNE) Increases By 45.4% www.americanbankingnews.com - April 12 at 1:09 AM
	Sorrento Therapeutics (SRNE) Given a $7.00 Price Target at Oppenheimer www.americanbankingnews.com - April 10 at 8:23 PM
	Sorrento Therapeutics Inc (SRNE) Receives Average Recommendation of "Buy" from Brokerages www.americanbankingnews.com - April 10 at 1:41 AM
	Sorrento Therapeutics (SRNE) PT Set at $7.00 by Oppenheimer www.americanbankingnews.com - April 9 at 11:59 PM
	Form 8-K Sorrento Therapeutics, For: Apr 05 www.streetinsider.com - April 5 at 5:17 PM
	Sorrento Therapeutics (SRNE), Celularity to Start Anti-CD38 CAR-T Phase 1 Clinical Trial in Patients With R/R Multiple ... www.streetinsider.com - April 5 at 5:17 PM
	Sorrento Therapeutics to Present at HC Wainwright Global Lifesciences Conference 04/09/18 globenewswire.com - April 5 at 5:17 PM
$Sorrento and Celularity to Start Anti-CD38 CAR-T Phase 1 Clinical Trial in Patients With Relapsed or Refractory Multiple Myeloma (NCT03464916)$	Sorrento and Celularity to Start Anti-CD38 CAR-T Phase 1 Clinical Trial in Patients With Relapsed or Refractory Multiple Myeloma (NCT03464916) finance.yahoo.com - April 5 at 5:17 PM
	Sorrento Therapeutics (SRNE) Upgraded at ValuEngine www.americanbankingnews.com - April 5 at 2:08 PM
	Sorrento Therapeutics to Present at H.C. Wainwright Global Lifesciences Conference 04/09/18 finance.yahoo.com - April 5 at 10:12 AM
	Sorrento Therapeutics Inc (SRNE) Expected to Announce Quarterly Sales of $4.50 Million www.americanbankingnews.com - April 5 at 5:56 AM
	HC Wainwright Reiterates Buy Rating for Sorrento Therapeutics (SRNE) www.americanbankingnews.com - April 3 at 7:49 AM
	Sorrento Therapeutics (SRNE) & Medpace (MEDP) Head to Head Contrast www.americanbankingnews.com - April 3 at 5:17 AM
	Zacks: Analysts Anticipate Sorrento Therapeutics Inc (SRNE) Will Announce Earnings of -$0.14 Per Share www.americanbankingnews.com - April 3 at 1:16 AM
	Sorrento Therapeutics (SRNE) Stock Rating Upgraded by ValuEngine www.americanbankingnews.com - March 31 at 12:42 PM
	Sorrento lists key milestones for 2018 seekingalpha.com - March 31 at 8:19 AM
	Why the Sudden Surge in Sorrento Therapeutics’ Revenue? finance.yahoo.com - March 29 at 5:29 PM
	Sorrento Therapeutics (SRNE) Downgraded by BidaskClub www.americanbankingnews.com - March 29 at 9:15 AM
	Your Daily Pharma Scoop: Sorrento Sell-Off, Bluebird/Celgene Agreement, Edge Therapeutics' Setback seekingalpha.com - March 29 at 8:29 AM
	Sorrento Therapeutics Chairman/CEO update to stockholders finance.yahoo.com - March 29 at 8:29 AM
	Why Sorrento Therapeutics Inc. Is Getting Beaten Down Today finance.yahoo.com - March 28 at 5:17 PM
	Sorrento Therapeutics Inc (SRNE) Sees Significant Increase in Short Interest www.americanbankingnews.com - March 28 at 2:02 AM
	Sorrento down 8% on convertible debt deal, cautious SA article seekingalpha.com - March 27 at 5:13 PM
	Sorrento Therapeutics Announces Unsecured $120.5M Convertible Note Financing finance.yahoo.com - March 27 at 8:29 AM
	BidaskClub Downgrades Sorrento Therapeutics (SRNE) to Buy www.americanbankingnews.com - March 24 at 12:28 PM
	Oppenheimer Comments on Sorrento Therapeutics Inc's Q1 2018 Earnings (SRNE) www.americanbankingnews.com - March 22 at 8:12 AM
	Oppenheimer Research Analysts Raise Earnings Estimates for Sorrento Therapeutics Inc (SRNE) www.americanbankingnews.com - March 21 at 4:02 PM

Sorrento Therapeutics (NASDAQ:SRNE) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Sorrento Therapeutics (NASDAQ:SRNE) Income Statement, Balance Sheet and Cash Flow Statement

Sorrento Therapeutics (NASDAQ SRNE) Stock Chart for Monday, May, 28, 2018

Loading chart…

This page was last updated on 5/28/2018 by MarketBeat.com Staff